A Phase 1, Randomized, Double-Blind, Two-Arm, Placebo-Controlled, Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of LJPC-401 in Healthy Adults
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Hepcidin (Primary)
- Indications Haemochromatosis; Iron overload
- Focus Adverse reactions
- Sponsors La Jolla Pharmaceutical Australia
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 23 Jan 2018 According to the australian New Zealand Clinical Trials Registry, One multiple dose cohort was enrolled during study conduct.
- 23 Jan 2018 Status changed from not yet recruiting to completed.